AI Insight
This study identifies SLC44A4, a choline transporter-like protein, as significantly downregulated in nasopharyngeal carcinoma (NPC) compared to normal tissue. Researchers found that when SLC44A4 is expressed at higher levels, it suppresses tumor growth, invasion, and metastasis while promoting B-cell infiltration and tertiary lymphoid structure (TLS) formation in the tumor microenvironment. Laboratory experiments demonstrated that restoring SLC44A4 expression in NPC cells reduced their aggressive behavior, altered cellular metabolism, and increased their sensitivity to DNA-damaging chemotherapy agents including cisplatin, doxorubicin, and olaparib.
Why it matters
SLC44A4 could serve as a biomarker to predict which NPC patients are most likely to respond to DNA damage-based chemotherapies, potentially enabling more personalized treatment strategies. The protein's association with B-cell infiltration and TLS formation suggests it may also help identify patients who could benefit from immunotherapy approaches.
Understand the Science
by Qian Liu, Yiyue Yin, Guangxian Hu, Hongde Li, Min Li, Xiangjian Luo, Wenbin Liu
Nasopharyngeal carcinoma (NPC) is characterized by aggressive progression, frequent metastasis, and heterogeneous therapeutic responses. Through integrated bulk transcriptomic datasets, single-cell analysis, clinical specimens, and NPC cell lines, we identified SLC44A4, a member of the choline transporter-like family, as a significantly downregulated gene in NPC. Transcriptomic analyses revealed that SLC44A4 expression was negatively associated with oxidative phosphorylation–related genes, DNA damage repair pathways, and malignant transcriptional programs related to proliferation, invasion, and metastasis. Moreover, SLC44A4-high tumors exhibited increased B-cell infiltration and enrichment of TLS-related transcriptional signatures. In vitro, SLC44A4 overexpression in NPC cells suppressed proliferation, colony formation, migration, and invasion, induced G0/G1 cell-cycle arrest, reduced expression of oxidative phosphorylation–related proteins, and selectively upregulated CXCL10. SLC44A4 overexpression also increased sensitivity to DNA-damaging agents, including temozolomide, doxorubicin, cisplatin, olaparib, and etoposide, while decreasing sensitivity to 5-fluorouracil. Together, these findings identify SLC44A4 as a potential tumor-suppressive factor in NPC and suggest that SLC44A4 may serve as a biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage–based therapies.